Back to dashboard
All PlansCoverageMedium impact

Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK)

Blue Cross & Blue Shield of Mississippi·MS · Oncology, Pulmonology, Pathology·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This is a fresh policy (1 day old) establishing coverage criteria for somatic biomarker testing including liquid biopsy for targeted treatment in non-small-cell lung cancer, covering multiple genetic markers (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK). The policy provides comprehensive background on genetic testing and FDA-approved targeted therapies but appears to be the introductory section without specific billing codes or coverage determinations.

Action Required

Action needed
Review the complete policy document to identify specific coverage criteria, prior authorization requirements, and billing codes for genetic biomarker testing. This appears to be a partial policy document focusing on clinical background. Billing team should obtain the full policy text including coverage determinations and billing guidelines before processing claims for NSCLC genetic testing.

Related policy hubs

Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK) | Blue Cross & Blue Shield of Mississippi | PolicyChanges.app